Welcome to our dedicated page for Alnylam Pharmaceuticals SEC filings (Ticker: ALNY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Alnylam Pharmaceuticals, Inc. (ALNY) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents offer detailed information on financial performance, capital structure, governance, and material events for a Nasdaq‑listed biopharmaceutical issuer focused on RNA interference (RNAi) therapeutics.
Investors can review current reports on Form 8‑K, where Alnylam reports quarterly financial results, material financing transactions, and other significant developments. Recent 8‑K filings describe quarterly results for periods in 2025, including discussions of net product revenues from AMVUTTRA, ONPATTRO, GIVLAARI, and OXLUMO, collaboration and royalty revenues, and the use of non‑GAAP financial measures. Other 8‑K filings outline a revolving credit facility, convertible senior note offerings, and partial repurchases of existing convertible notes, giving insight into the company’s liquidity and leverage.
Filings also cover governance and compensation matters, such as changes to the Board of Directors and updates to executive roles and compensation in connection with organizational changes in research and development. These disclosures help readers understand how Alnylam structures its leadership and aligns incentives as it advances its pipeline and commercial portfolio.
Through Stock Titan, users can track ALNY’s SEC submissions as they are made available on EDGAR and use AI‑powered summaries to interpret complex sections of lengthy filings. This includes identifying key points in quarterly and annual reports, highlighting notable items in 8‑Ks, and surfacing information about direct financial obligations, credit agreements, and other events that may affect the company’s risk profile. The filings page is a resource for analyzing how Alnylam reports on its RNAi business, capital markets activity, and corporate governance over time.
Alnylam Pharmaceuticals (ALNY) reported a proposed sale under Rule 144 of 31,448 common shares valued at $13,635,538.00 based on the filing. The shares were acquired and are to be sold on 08/14/2025 through UBS Financial Services, Inc. via the exercise of stock options and paid in cash. The filing lists 131,079,015 shares outstanding for the class. The filer reports no shares sold in the past three months. The notice includes the signer’s representation that they are unaware of any undisclosed material adverse information about the issuer.
Alnylam Pharmaceuticals announced significant organizational changes with the combination of its Research and Early Development function and Development function into a single R&D organization. Key leadership appointments include:
- Dr. Pushkal Garg promoted to Executive VP, Chief Research and Development Officer with new compensation package: - Base salary: $825,000 - Annual incentive target: 65% of base salary - Long-term equity incentives to be determined
- Dr. Kevin Fitzgerald (Executive VP, Chief Scientific Officer) receives expanded responsibilities for external innovation with: - Increased annual incentive target to 60% of base salary - One-time restricted stock unit grant valued at $2.5M, vesting over 3 years
This strategic reorganization aims to streamline R&D operations and strengthen the company's innovation capabilities. The changes were approved by the People, Culture and Compensation Committee on June 12, 2025, with formal announcement made on June 18, 2025.